Look At Elicio's Pipeline: What Does This Cancer-Fighting Company Have In Store For The Future?
Elicio Therapeutics Inc. is using precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors. Founded in 2011, the company has developed an innovative pipeline of cancer immunotherapies addressing critical unmet needs.
Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008.
Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008.
Category
🗞
NewsTranscript
00:00 Elysio Therapeutics Inc., trading on the Nasdaq under ELTX, is a company founded in 2011 working
00:08 on advanced cancer treatments using vaccines and therapies that trigger the body's immune
00:12 system to fight cancer.
00:13 They have three main vaccine candidates, ELI-002, ELI-007, and ELI-008.
00:21 ELI-002 targets a specific mutation, KRAS, found in 25% of solid tumors.
00:28 It stimulates the immune system to attack cancer cells.
00:31 The vaccine is designed to cover seven common KRAS mutations.
00:36 ELI-007 is a vaccine for cancers with BRAF V600E mutations present in melanoma, colon,
00:44 and lung cancers.
00:45 It aims to sustain immune responses, addressing resistance issues seen with current treatments.
00:50 ELI-008 targets mutations in P53 found in many cancers.
00:55 The vaccine enhances immune response in draining lymph nodes to eliminate tumor tissue.
01:00 Elysio Therapeutics is conducting trials to ensure these treatments are effective and
01:03 can reach a broader range of patients.
01:06 Their approach involves precise targeting of lymph nodes, crucial in orchestrating the
01:09 immune response against cancer.
01:11 Overall, they are at the forefront of cancer treatment through vaccination, combining expertise
01:16 in immunology and immunotherapy.
01:18 [MUSIC PLAYING]